{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T19:54:23Z","timestamp":1787860463099,"version":"build-2784847793"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,12,18]],"date-time":"2020-12-18T00:00:00Z","timestamp":1608249600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,12,18]],"date-time":"2020-12-18T00:00:00Z","timestamp":1608249600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Rheumatol"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1038\/s41584-020-00562-2","type":"journal-article","created":{"date-parts":[[2020,12,18]],"date-time":"2020-12-18T12:03:37Z","timestamp":1608293017000},"page":"71-72","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":124,"title":["Rheumatic disease and COVID-19: epidemiology and outcomes"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8242-9262","authenticated-orcid":false,"given":"Kimme L.","family":"Hyrich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8411-7972","authenticated-orcid":false,"given":"Pedro M.","family":"Machado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,12,18]]},"reference":[{"key":"562_CR1","unstructured":"World Health Organization. WHO Coronavirus Disease (COVID-19) Dashboard, https:\/\/covid19.who.int\/ (2020)."},{"key":"562_CR2","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/s41586-020-2521-4","volume":"584","author":"EJ Williamson","year":"2020","unstructured":"Williamson, E. J. et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature 584, 430\u2013436 (2020).","journal-title":"Nature"},{"key":"562_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17703-6","volume":"11","author":"D Simon","year":"2020","unstructured":"Simon, D. et al. Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion. Nat. Commun. 11, 3774 (2020).","journal-title":"Nat. Commun."},{"key":"562_CR4","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1136\/annrheumdis-2020-217871","volume":"79","author":"M Gianfrancesco","year":"2020","unstructured":"Gianfrancesco, M. et al. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann. Rheum. Dis. 79, 859\u2013866 (2020).","journal-title":"Ann. Rheum. Dis."},{"key":"562_CR5","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1136\/annrheumdis-2019-216516","volume":"79","author":"A Sepriano","year":"2020","unstructured":"Sepriano, A. et al. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann. Rheum. Dis. 79, 760\u2013770 (2020).","journal-title":"Ann. Rheum. Dis."},{"key":"562_CR6","doi-asserted-by":"publisher","first-page":"m2980","DOI":"10.1136\/bmj.m2980","volume":"370","author":"RAC Siemieniuk","year":"2020","unstructured":"Siemieniuk, R. A. C. et al. Drug treatments for COVID-19: living systematic review and network meta-analysis. BMJ 370, m2980 (2020).","journal-title":"BMJ"},{"key":"562_CR7","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1136\/annrheumdis-2020-218694","volume":"79","author":"KL Winthrop","year":"2020","unstructured":"Winthrop, K. L. & Mariette, X. To immunosuppress: whom, when and how? That is the question with COVID-19. Ann. Rheum. Dis. 79, 1129\u20131131 (2020).","journal-title":"Ann. Rheum. Dis."},{"key":"562_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(20)30404-5","author":"DE Leisman","year":"2020","unstructured":"Leisman, D. E. et al. Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes. Lancet Respir. Med. https:\/\/doi.org\/10.1016\/S2213-2600(20)30404-5 (2020).","journal-title":"Lancet Respir. Med."},{"key":"562_CR9","doi-asserted-by":"publisher","first-page":"157","DOI":"10.3389\/fmolb.2020.00157","volume":"7","author":"B Zhang","year":"2020","unstructured":"Zhang, B. et al. Immune phenotyping based on the neutrophil-to-lymphocyte ratio and IgG level predicts disease severity and outcome for patients with COVID-19. Front. Mol. Biosci. 7, 157 (2020).","journal-title":"Front. Mol. Biosci."},{"key":"562_CR10","unstructured":"COVID-19 Global Rheumatology Alliance. Healthcare Provider Entered Registries, https:\/\/rheum-covid.org\/provider-registry-gate\/ (2020)."}],"container-title":["Nature Reviews Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41584-020-00562-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41584-020-00562-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41584-020-00562-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T22:21:21Z","timestamp":1684621281000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41584-020-00562-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,18]]},"references-count":10,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["562"],"URL":"https:\/\/doi.org\/10.1038\/s41584-020-00562-2","relation":{},"ISSN":["1759-4790","1759-4804"],"issn-type":[{"value":"1759-4790","type":"print"},{"value":"1759-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,18]]},"assertion":[{"value":"18 December 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"K.L.H. declares that she has received consulting and speaker\u2019s fees from Abbvie and grant income from BMS, Pfizer and UCB, all unrelated to this manuscript. P.M.M. has received consulting and speaker\u2019s fees from Abbvie, BMS, Celgene, Eli Lilly, Janssen, MSD, Novartis, Orphazyme, Pfizer, Roche and UCB, all unrelated to this manuscript.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}